Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nastul Compuesto is a fixed-dose combination medication developed and marketed by Chemopharma, primarily indicated for the symptomatic relief of the common cold, influenza, and other upper respiratory tract infections. It integrates three active pharmaceutical ingredients: paracetamol (acetaminophen), which provides analgesic and antipyretic effects by inhibiting prostaglandin synthesis in the central nervous system; pseudoephedrine, a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-adrenergic receptors to produce vasoconstriction; and chlorphenamine (chlorpheniramine), a first-generation antihistamine that antagonizes H1 receptors to alleviate allergic-like symptoms such as sneezing, rhinorrhea, and itchy eyes. The product is widely used in the Chilean market as an 'antigripal' (anti-flu) treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + pseudoephedrine + chlorphenamine.